Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer’s disease

Author： Cummings J.L.   Ringman J.M.  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.8, Iss.4, 1999-04, pp. : 463-471

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease

By Heydorn W.E.  

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 10, 1997-10 ,pp. : 1527-1537

Informa Healthcare

Access to resources Recommend Favorite

A Review of Clinical Pharmacokinetics and Pharmacodynamics of Galantamine, a Reversible Acetylcholinesterase Inhibitor for the Treatment of Alzheimer 's Disease, in Healthy Subjects and Patients

By  

Current Clinical Pharmacology, Vol. 5, Iss. 2, 2010-05 ,pp. : 115-124

Bentham Science Publishers

Access to resources Recommend Favorite

Metrifonate: A Review of its Use in Alzheimer’s Disease

By Ormrod D.   Spencer C.  

CNS Drugs, Vol. 13, Iss. 6, 2000-06 ,pp. : 443-467

Adis International

Access to resources Recommend Favorite

Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease: review and current status

By Gottwald M.D.   Rozanski R.I.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. : 1673-1682

Informa Healthcare

Access to resources Recommend Favorite

The pharmacology of donepezil: a new treatment for Alzheimer’s disease

By Wilkinson D.G.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 1, 1999-11 ,pp. : 121-135

Informa Healthcare

Access to resources Recommend Favorite